Trade-Ideas LLC identified

Cesca Therapeutics

(

KOOL

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Cesca Therapeutics as such a stock due to the following factors:

  • KOOL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $10.2 million.
  • KOOL traded 175,279 shares today in the pre-market hours as of 8:08 AM, representing 10.6% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in KOOL with the Ticky from Trade-Ideas. See the FREE profile for KOOL NOW at Trade-Ideas

More details on KOOL:

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the United States and internationally. Currently there are no analysts that rate Cesca Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Cesca Therapeutics has been 542,300 shares per day over the past 30 days. Cesca has a market cap of $12.2 million and is part of the health care sector and health services industry. The stock has a beta of -1.27 and a short float of 15.1% with 0.12 days to cover. Shares are up 14.8% year-to-date as of the close of trading on Friday.

TST Recommends

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Cesca Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 126.0% when compared to the same quarter one year ago, falling from -$4.81 million to -$10.87 million.
  • Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, CESCA THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for CESCA THERAPEUTICS INC is rather low; currently it is at 22.07%. It has decreased significantly from the same period last year. Along with this, the net profit margin of -383.93% is significantly below that of the industry average.
  • Net operating cash flow has decreased to -$3.86 million or 11.86% when compared to the same quarter last year. Despite a decrease in cash flow of 11.86%, CESCA THERAPEUTICS INC is in line with the industry average cash flow growth rate of -21.64%.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 72.17%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 66.66% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.